Orexo and Janssen terminate arachidonic acid deal
This article was originally published in Scrip
Executive Summary
Orexo and Janssen Pharmaceuticals have decided to end their research collaboration and licence agreement regarding the OX-CLI and OX-ESI programmes and a third, undisclosed Janssen programme.